Liver Diseases  >>  beclabuvir (BMS-791325)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beclabuvir (BMS-791325) / BMS
HEPCAT, NCT01193361: Ph IIA Study (SOC +/- NS5B)

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2a
39
US
BMS-791325, Placebo, Peg-interferon alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
06/11
11/12
NCT01455090: Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark CROI 2014
More
Completed
2
320
US, Europe
BMS-650032, Asunaprevir (ASV), BMS-790052, Daclatasvir (DCV), BMS-791325, Ribavirin, Copegus®
Bristol-Myers Squibb
Chronic Hepatitis C
03/14
07/15
QUATTROTURBO, NCT02309450: Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

Withdrawn
2
0
Europe
.Asunaprevir, Daclatasvir and BMS - 791325
ANRS, Emerging Infectious Diseases, Bristol-Myers Squibb
Hepatitis C Virus Genotype 4 Infection
11/15
08/16
NCT00664625: A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Checkmark
Apr 2014 - Apr 2014: 
Completed
1/2
24
US, RoW
BMS-791325, Placebo
Bristol-Myers Squibb
Chronic Hepatitis C
06/09
06/09

Download Options